Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15482236 | 0.90 | MAPT (0.57) | KDM4EALDH1A1HPGDGAAMAPK1 | |
| SCHEMBL15482244 | 0.81 | HPGD (0.69) | KDM4EALDH1A1HPGDMAPK1MAPT | |
| SCHEMBL15480590 | 0.79 | MAPT (0.68) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL15480599 | 0.79 | SMN1; SMN2 (0.51) | KDM4EALDH1A1HPGDGAAMAPK1 | |
| SCHEMBL15482262 | 0.78 | HDAC6 (0.64) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL15480596 | 0.78 | SMN1; SMN2 (0.57) | ALDH1A1GAAMAPK1LMNASMN1; SMN2 | |
| SCHEMBL15480657 | 0.78 | HDAC6 (0.46) | ALDH1A1MAPK1MAPTLMNAUSP2 | |
| SCHEMBL15480631 | 0.77 | HPGD (0.47) | KDM4EALDH1A1HPGDGAAMAPK1 | |
| SCHEMBL15480601 | 0.77 | SIRT2 (0.56) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL15482278 | 0.77 | LMNA (0.57) | KDM4EALDH1A1HPGDGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KDM4E 330/4885ALDH1A1 3068/4885HPGD 1305/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | KDM4E 330/4885ALDH1A1 3068/4885HPGD 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.